A dose-finding study of carboplatin–epirubicin–docetaxel in advanced epithelial ovarian cancer

The docetaxel–carboplatin combination is active and well tolerated in patients with epithelial ovarian cancer. We added epirubicin to this combination to investigate additional benefits of anthracyclines in epithelial ovarian cancer. Twenty-one patients, FIGO Ic-IV, performance status 0–1, were trea...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Neill, V J, Kaye, S B, Reed, N S, Paul, J, Davis, J A, Vasey, P A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375366/
https://www.ncbi.nlm.nih.gov/pubmed/11986768
http://dx.doi.org/10.1038/sj.bjc.6600259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375366/
https://www.ncbi.nlm.nih.gov/pubmed/11986768
http://dx.doi.org/10.1038/sj.bjc.6600259

Ejemplares similares